A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Completed · Phase 1

Conditions studied: Renal Impairment

In brief

The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.

Key facts

Study ID

NCT00750620

Run by

Astellas Pharma Inc

People needed

33

Starts

2008-09-01

Expected to finish

2009-09-01

Last updated by the study team

2013-09-05

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• good health other than renal impairment
• body mass index (BMI) between 18 and 40 kg/m2

You may not qualify if…

• subject with renal impairment has not been on stable dose of concomitant medication for at least 2 weeks
• subject has liver enzyme abnormalities

Where it is running

• Study site — Anaheim, California, United States
• Study site — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.